Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 523

1.

NMO-IgG predicts the outcome of recurrent optic neuritis.

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG.

Neurology. 2008 Jun 3;70(23):2197-200. doi: 10.1212/01.wnl.0000303817.82134.da. Epub 2008 Apr 23.

PMID:
18434643
2.

Neuromyelitis optica IgG status in acute partial transverse myelitis.

Scott TF, Kassab SL, Pittock SJ.

Arch Neurol. 2006 Oct;63(10):1398-400.

PMID:
17030654
3.

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA.

Ann Neurol. 2006 Mar;59(3):566-9.

PMID:
16453327
4.

Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.

Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ.

Neurology. 2008 Jan 29;70(5):344-52. Epub 2007 Dec 19.

PMID:
18094334
5.

Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ.

Arch Neurol. 2009 Sep;66(9):1164-7. doi: 10.1001/archneurol.2009.188.

PMID:
19752309
6.

Neuromyelitis optica antibodies in patients with severe optic neuritis in China.

Lai C, Tian G, Takahashi T, Liu W, Yang L, Zhang X.

J Neuroophthalmol. 2011 Mar;31(1):16-9. doi: 10.1097/WNO.0b013e3181f8a693.

PMID:
21150455
7.

Neuromyelitis optica and non organ-specific autoimmunity.

Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG.

Arch Neurol. 2008 Jan;65(1):78-83. doi: 10.1001/archneurol.2007.17.

PMID:
18195142
8.

Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.

McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ.

Arch Neurol. 2009 Sep;66(9):1134-8. doi: 10.1001/archneurol.2009.178.

PMID:
19752303
9.

Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.

Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W.

Semin Ophthalmol. 2008 May-Jun;23(3):191-200. doi: 10.1080/08820530802049921.

PMID:
18432545
10.

[Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital].

Vaknin-Dembinsky A, Levin N, Raz N, Abramsky O, Karussis D, Brill L, Petrou P, Ovadia H.

Harefuah. 2013 Feb;152(2):101-5, 122. Hebrew.

PMID:
23513502
11.

Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies.

Cabrera-Gómez JA, Bonnan M, González-Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, Graus F, Smadja D, Merle H, Thomas L, Gómez-García A, Cabre P.

Mult Scler. 2009 Jul;15(7):828-33. doi: 10.1177/1352458509104585. Epub 2009 Jun 4.

PMID:
19498017
12.

Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.

Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N, Munschauer F, Zivadinov R, Ramanathan M.

Mult Scler. 2008 Sep;14(8):1061-7. doi: 10.1177/1352458508092811. Epub 2008 Jun 23.

PMID:
18573816
13.

Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.

Chan KH, Ramsden DB, Yu YL, Kwok KH, Chu AC, Ho PW, Kwan JS, Lee R, Lim E, Kung MH, Ho SL.

Eur J Neurol. 2009 Mar;16(3):310-6. doi: 10.1111/j.1468-1331.2008.02376.x.

PMID:
19138340
14.

NMO-IgG and Devic's neuromyelitis optica: a French experience.

Marignier R, De Sèze J, Vukusic S, Durand-Dubief F, Zéphir H, Vermersch P, Cabre P, Cavillon G, Honnorat J, Confavreux C.

Mult Scler. 2008 May;14(4):440-5. doi: 10.1177/1352458507084595. Epub 2008 Jan 21.

PMID:
18208892
15.

Aquaporin-4 autoantibodies in a paraneoplastic context.

Pittock SJ, Lennon VA.

Arch Neurol. 2008 May;65(5):629-32. doi: 10.1001/archneur.65.5.629. Erratum in: Arch Neurol. 2008 Oct;65(10):1394.

PMID:
18474738
16.

Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica.

Robinson-Agramonte MA, Gonçalves CA, Portela LV, Saiz-Hinarejos A, Oses JP, Motta LS, Muller AP, Marquez Gonzalez ME, Souza DO.

Neuroimmunomodulation. 2010;17(3):177-9. doi: 10.1159/000258717. Epub 2010 Feb 4. Erratum in: Neuroimmunomodulation. 2010;17(6):378. Portela, Valmor L [corrected to Portela, L. Valmor]; Oses, Pierre J [corrected to Oses, Jean Pierre]; Motta, Souza L [corrected to Motta, Luis Souza]; Gomes de Souza, Onofre D [corrected to Souza, Diogo Onofre].

PMID:
20134196
17.

Diagnosis and treatment of neuromyelitis optica.

Wingerchuk DM.

Neurologist. 2007 Jan;13(1):2-11. Review.

PMID:
17215722
18.

Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y.

Tohoku J Exp Med. 2006 Dec;210(4):307-13.

19.

[Evaluation of diagnostic value for NMO-IgG in patients with neuromyelitis optica].

Yang Y, Huang DH, Wu L, Wu WP.

Zhonghua Yi Xue Za Zhi. 2010 Mar 9;90(9):606-9. Chinese.

PMID:
20450783
20.

Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.

Magaña SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF.

Arch Neurol. 2009 Aug;66(8):964-6. doi: 10.1001/archneurol.2009.152.

Supplemental Content

Support Center